Increased microRNA-30a levels in bronchoalveolar lavage fluid as a diagnostic biomarker for lung cancer

PeerJ

卷:9

Huan Liu¹  Bo-Jiang Chen²  Yu-Chen Zhang²  Feng-Ming Luo²  Ling Sun²  Ying-Ying Zhu²  Wen-Jun Zhu² 

[1]Department of General Medicine, University-Town Hospital of Chongqing Medical University, Chongqing, China

[2]|Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China

关键词: miRNA-30a;    Lung cancer;    Bronchoalveolar lavage fluid (BALF);    Tumor marker;    Early diagnosis;    Biomarker;   

DOI  :  10.7717/peerj.11528

来源: DOAJ

【 摘 要 】

Background MicroRNA-30a (miRNA-30a) levels have been shown to increase in the plasma of lung cancer patients. Herein, we evaluated the miRNA-30a levels in the bronchoalveolar lavage fluid (BALF) of lung cancer patients as a potential biomarker for lung cancer diagnosis. Methods BALF miRNA-30a expression of 174 subjects was quantified using quantitative real-time reverse transcription-polymerase chain reaction and compared between lung cancer patients and control patients with benign lung diseases. Moreover, its diagnostic value was evaluated by performing receiver operating characteristic (ROC) curve analysis. Results The relative BALF miRNA-30a expression was significantly higher in the lung cancer patients than in the controls (0.74 ±  0.55 versus 0.07 ±  0.48, respectively, p < 0.001) as well as in lung cancer patients with stage I–IIA disease than in those with stage IIB–IV disease (0.98 ±  0.64 versus 0.66 ±  0.54, respectively, p < 0.05). Additionally, miRNA-30a distinguished benign lung diseases from lung cancers, with an area under the ROC curve (AUC) of 0.822. ROC analysis also revealed an AUC of 0.875 for the Youden index-based optimal cut-off points for stage I–IIA adenocarcinoma. Thus, increased miRNA-30a levels in BALF may be a useful biomarker for non-small-cell lung cancer diagnosis.

【 授权许可】

Unknown